Healthcare
Listen: Pharma 2026 - higher prices, manufacturing migration, China’s ascent
Are President Trump's pharmaceutical policies a seismic revolution or mostly hot air? Will he succeed in lowering drug prices in 2026? Will manufacturing shift back to the US? And what does it all mean for Europe and China? In this podcast, ING's Diederik Stadig and Stephen Farrelly share their outlook for the year ahead
In this podcast, Diederik Stadig, ING's healthcare and tech economist, and Stephen Farrelly, global lead for pharma and healthcare, join editors Rebecca Byrne and Olivia Grace to discuss President Trump’s pharmaceutical policy, and the implications for branded and generic medicines around the world in 2026 and beyond.
Content Disclaimer
This publication has been prepared by ING solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Read more
This publication has been prepared by ING solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Read more
Download
Download article